Ana Isabel Aller

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

Ana Espinel‐Ingroff, Ana Isabel Aller, Laura Rosío Castañón-Olivares et al. · Antimicrobial Agents and Chemotherapy · 2012 · 246 citations · Full text

Diagnostic Mycology, Pathogenic Microbiology, Pathogen Detection +17

Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection

Ana Isabel Aller, Estrella Martín‐Mazuelos, Fernando Lozano et al. · Antimicrobial Agents and Chemotherapy · 2000 · 169 citations · Full text

Evaluation of CHROMagar candida medium for the isolation and presumptive identification of species of candida of clinical importance

Samuel Bernal, Estrella Martín‐Mazuelos, Martha Martínez-Garcia et al. · Diagnostic Microbiology and Infectious Disease · 1996 · 67 citations

Antifungal Agent, Clinical Importance, Vaginitis +9

Molecular identification, antifungal resistance and virulence of <i>Cryptococcus neoformans</i> and <i>Cryptococcus deneoformans</i> isolated in Seville, Spain

Sara Gago, Carmen Serrano, Ana Alastruey‐Izquierdo et al. · Mycoses · 2016 · 46 citations

Evaluation of Disk Diffusion Method for Determining Posaconazole Susceptibility of Filamentous Fungi: Comparison with CLSI Broth Microdilution Method

E. López-Oviedo, Ana Isabel Aller, Craig A. Martin et al. · Antimicrobial Agents and Chemotherapy · 2006 · 45 citations · Full text

Mold Control, Diagnostic Mycology, Microbial Contamination +11